number of small entities under the criteria of the Regulatory Flexibility Act. List of Subjects in 14 CFR Part 97

Air traffic control, Airports, Incorporation by reference, Navigation (air).

Issued in Washington, DC, on May 18, 2018.

John S. Duncan, Executive Director, Flight Standards Service.

Adoption of the Amendment

Accordingly, pursuant to the authority delegated to me, Title 14, Code of Federal Regulations, part 97 (14 CFR part 97) is amended by establishing, amending, suspending, or removing Standard Instrument Approach Procedures and/or Takeoff Minimums and Obstacle Departure Procedures effective at 0901 UTC on the dates specified, as follows:

PART 97—STANDARD INSTRUMENT APPROACH PROCEDURES

1. The authority citation for part 97 continues to read as follows:

Authority: 49 U.S.C. 106(f), 106(g), 40103, 40106, 40113, 40114, 40120, 44502, 44514, 44701, 44719, 44721–44722.

2. Part 97 is amended to read as follows:

Effective 21 June 2018

Fort Madison, IA, Fort Madison Muni, RNAV (GPS) RWY 17, Amdt 1A

Big Rapids, MI, Roben-Hood, Takeoff Minimums and Obstacle DP, Amdt 6A

Detroit, MI, Detroit Metropolitan Wayne County, ILS OR LOC RWY 22L, ILS RWY 22L SA CAT I, Amdt 32A

Detroit, MI, Detroit Metropolitan Wayne County, RNAV (RNP) W RWY 22R, Orig-A

Detroit, MI, Detroit Metropolitan Wayne County, RNAV (RNP) X RWY 3R, Orig-A

Detroit, MI, Detroit Metropolitan Wayne County, RNAV (RNP) X RWY 21L, Orig-A

St Paul, MN, St Paul Downtown Holman Fld, ILS OR LOC RWY 32, Amdt 6A

Omaha, NE, Eppley Airfield, RNAV (GPS) Y RWY 18W, Amdt 4A

Saranac Lake, NY, Adirondack Rgnl, Takeoff Minimums and Obstacle DP, Amdt 8

Cleveland, OH, Cleveland-Hopkins Intl, RNAV (GPS) Y RWY 6L, Amdt 2A

Ottawa, OH, Putnam County, VOR RWY 27, Amdt 2C

Effective 19 July 2018

Manley Hot Springs, AK, Manley Hot Springs, RNAV (GPS) RWY 18, Orig

Manley Hot Springs, AK, Manley Hot Springs, RNAV (GPS) RWY 36, Orig

Manley Hot Springs, AK, Manley Hot Springs, RNAV (GPS) RWY 34, Amdt 4

Fayetteville/Springdale/Rogers, AR, Northwest Arkansas Rgnl, ILS OR LOC RWY 34, Amdt 4

Auburn, CA, Auburn Muni, RNAV (GPS) RWY 7, Orig-B

Long Beach, CA, Long Beach/Daugherty Field/ ILS OR LOC RWY 30, Amdt 34

Long Beach, CA, Long Beach/Daugherty Field/, RNAV (RNP) RWY 26R, Amdt 1A

Oakland, CA, Metropolitan Oakland Intl, RNAV (RNP) Z RWY 12, Amdt 2

Palm Springs, CA, Jacqueline Cochran Rgnl, RNAV (GPS) RWY 30, Amdt 1

Palm Springs, CA, Jacqueline Cochran Rgnl, VOR RWY 30, Amdt 2

Palm Springs, CA, Jacqueline Cochran Rgnl, VOR-A, Amdt 1

Panama City, FL, Northwest Florida Beaches Intl, ILS OR LOC RWY 16, ILS RWY 16 SA CAT I, Amdt 3

Detroit, MI, Metropolitan Wayne County, RNAV (RNP) X RWY 21L, Orig-A

Kahului, HI, Kahului, ILS OR LOC RWY 2, Amdt 25A

Springfield, IL, Abraham Lincoln Capital, VOR RWY 4, Orig-C

Sterling/Rockfalls, IL, Whiteside Co Arpt-Jos H Bittorf Fld, ILS OR LOC RWY 25, Amdt 11

Sterling/Rockfalls, IL, Whiteside Co Arpt-Jos H Bittorf Fld, LOC BC RWY 7, Amdt 6

Sterling/Rockfalls, IL, Whiteside Co Arpt-Jos H Bittorf Fld, NDB RWY 7, Amdt 6, CANCELED

Sterling/Rockfalls, IL, Whiteside Co Arpt-Jos H Bittorf Fld, RNAV (GPS) RWY 7, Amdt 1

Sterling/Rockfalls, IL, Whiteside Co Arpt-Jos H Bittorf Fld, RNAV (GPS) RWY 25, Amdt 1

Howell, MI, Livingston County Spencer J Hardy, RNAV (GPS) RWY 31, Amdt 1B

Howell, MI, Livingston County Spencer J Hardy, VOR RWY 31, Amdt 11A, CANCELED

Menomonie, WI, Menomonie Rgnl, ILS OR LOC RWY 3, Amdt 3

Menomonie, WI, Menomonie Rgnl, RNAV (GPS) RWY 3, Orig-A

Menomonie, WI, Menomonie Rgnl, RNAV (GPS) RWY 21, Orig-C

Menomonie, WI, Menomonie Rgnl, RNAV (GPS) RWY 32, Amdt 1C

Menomonie, WI, Menomonie Rgnl, Takeoff Minimums and Obstacle DP, Amdt 3A

Menomonie, WI, Menomonie Rgnl, VOR-A, Amdt 3C

Cabool, MO, Cabool Memorial, RNAV (GPS) RWY 21, Orig-B

Cabool, MO, Cabool Memorial, VOR/DME RWY 21, Amdt 2A, CANCELED

Ithaca, NY, Ithaca Tompkins Rgnl, ILS OR LOC RWY 32, Amdt 7

Ithaca, NY, Ithaca Tompkins Rgnl, RNAV (GPS) RWY 32, Orig-B

Ithaca, NY, Ithaca Tompkins Rgnl, VOR RWY 14, Amdt 14A, CANCELED

Ogdensburg, NY, Ogdensburg Intl, RNAV (GPS) RWY 9, Amdt 1

Watertown, NY, Watertown Intl, Takeoff Minimums and Obstacle DP, Amdt 3

Tiffin, OH, Seneca County, RNAV (GPS) RWY 6, Orig-B

Tiffin, OH, Seneca County, RNAV (GPS) RWY 24, Amdt 1C

Tiffin, OH, Seneca County, VOR RWY 6, Amdt 9B

Anderson, SC, Anderson Rgnl, RNAV (GPS) RWY 23, Amdt 2

Welleslaxo, TX, Mid Valley, RNAV (GPS) RWY 14, Orig-A

Welleslaxo, TX, Mid Valley, VOR-A, Orig-B

Eastsound, WA, Orcas Island, RNAV (GPS) RWY 16, Amdt 2

Port Angeles, WA, William R Fairchild Intl, ILS OR LOC RWY 8, Amdt 3A

Port Angeles, WA, William R Fairchild Intl, RNAV (GPS) RWY 8, Amdt 1A

Port Angeles, WA, William R Fairchild Intl, RNAV (GPS) RWY 26, Amdt 1B

Port Angeles, WA, William R Fairchild Intl, Takeoff Minimums and Obstacle DP, Amdt 3A

Port Angeles, WA, William R Fairchild Intl, WATTR SEVEN, Graphic DP

New Holsteina, WI, New Holsteina Muni, RNAV (GPS) RWY 14, Orig-B

[FR Doc. 2018–11836 Filed 6–4–18; 8:45 am]

BILLING CODE 4910–13–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Parts 862, 866, 876, 880, and 884

[Docket No. FDA–2017–N–1129]

Medical Devices; Exemptions From Premarket Notification: Class II Devices

AGENCY: Food and Drug Administration, HHS.

ACTION: Final order.

SUMMARY: The Food and Drug Administration (FDA or the Agency) is publishing an order to exempt a list of class II devices from premarket notification (510(k)) requirements, subject to certain limitations. This exemption from 510(k), subject to certain limitations, is immediately in effect for the listed class II devices. This exemption will decrease regulatory burdens on the medical device industry and will eliminate private costs and expenditures required to comply with certain Federal regulations. FDA is also amending the codified language for the listed class II devices to reflect this final determination. FDA is publishing this order in accordance with the section of the Federal Food, Drug, and Cosmetic Act (FD&C Act) permitting the exemption of a device from the requirement to submit a 510(k).

DATES: This order is effective June 5, 2018.

FOR FURTHER INFORMATION CONTACT: Scott McFarland, Center for Devices and

Human Services
Radiological Health (CDRH), Food and Drug Administration, 10903 New Hampshire Ave, Bldg. 66, Rm. 4676, Silver Spring, MD 20993–0002, 301–796–6217.

SUPPLEMENTARY INFORMATION:

I. Statutory Background

Section 510(k) of the FD&C Act (21 U.S.C. 360(k)) and the implementing regulations, 21 CFR part 807, subpart E, require persons who intend to market a new device to submit to obtain clearance of a premarket notification (510(k)) containing information that allows FDA to determine whether the new device is “substantially equivalent” within the meaning of section 513(i) of the FD&C Act (21 U.S.C. 360(i)) to a legally marketed device that does not require premarket approval.

On December 13, 2016, the 21st Century Cures Act (Cures Act) (Pub. L. 114–255) was signed into law. Section 3054 of the Cures Act amended section 510(n) of the FD&C Act. As amended, section 510(n)(2) provides that, 1 calendar day after the date of publication of the final list under section 510(1)(B), FDA may exempt a class II device from the requirement to submit a report under section 510(k) of the FD&C Act, upon its own initiative or a petition of an interested person, if FDA determines that a 510(k) is not necessary to provide reasonable assurance of the safety and effectiveness of the device. This section requires FDA to publish in the Federal Register a notice of intent to exempt a device, or of the petition, and provide a 60-calendar-day comment period. Within 120 days of publication of such notice, FDA shall publish an order in the Federal Register that sets forth its final determination regarding the exemption of the device that was the subject of the notice.

II. Criteria for Exemption

There are a number of factors FDA may consider to determine whether a 510(k) is necessary to provide reasonable assurance of the safety and effectiveness of a class II device. These factors are discussed in the January 21, 1998, Federal Register notice (63 FR 3142) and subsequently in the guidance the Agency issued on February 19, 1998, entitled “Procedures for Class II Device Exemptions from Premarket Notification, Guidance for Industry and CDRH Staff” (“Class II 510(k) Exemption Guidance”). That guidance can be obtained through the internet at https://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM080199.pdf or by sending an email request to CDRH-Guidance@fda.hhs.gov to receive a copy of the document. Please use the document number 159 to identify the guidance you are requesting.

Accordingly, FDA generally considers the following factors to determine whether premarket notification is necessary for class II devices: (1) The device does not have a significant history of false or misleading claims or of risks associated with inherent characteristics of the device; (2) characteristics of the device necessary for its safe and effective performance are well established; (3) changes in the device that could affect safety and effectiveness will either (a) be readily detectable by users by visual examination or other means such as routine testing, before causing harm, or (b) not materially increase the risk of injury, incorrect diagnosis, or ineffective treatment; and (4) any changes to the device would not be likely to result in a change in the device’s classification. FDA may also consider that, even when exempting devices, those devices would still be subject to the limitations on exemptions.

III. Comments on the Proposed Exemption and FDA Response

In the Federal Register of November 7, 2017 (82 FR 51633), FDA published a notice (“November 2017 notice”) announcing its intent to exempt, upon its own initiative, certain class II devices listed in table 1 from 510(k) requirements, subject to certain limitations, and provided opportunity for interested persons to submit comments by January 8, 2018. After reviewing comments received, FDA is now providing its final determination on exempting the certain class II devices listed in table 1 from 510(k) requirements, subject to certain limitations as identified in this order. FDA is also amending the codified language for the classification regulations for the certain class II devices listed in table 1 to reflect this final determination. Persons with pending 510(k) submissions for devices that are now exempt from 510(k), subject to the limitations, should withdraw their submissions.

In response to the November 2017 notice announcing FDA’s intent to exempt those device types from 510(k) requirements, FDA received a submission from one commenter—a professional organization—opposing an exemption from 510(k) for the genetic health risk assessment test device type. To maximize clarification of comments and our responses, the word “Comment” appears in parentheses before the comment’s description, and the word “Response” in parentheses precedes the response. Specific issues raised by the comment and the Agency’s response follows.

(Comment) The commenter recommended FDA not exempt one-time FDA reviewed genetic health risk assessment system devices from the 510(k) requirement because there would be insufficient oversight to ensure the analytical and clinical validity of these tests, consumers would be misled regarding which tests FDA has affirmed are scientifically valid, and concerns that, if one-time FDA reviewed genetic health risk assessment system devices were exempted, consumers would not be assured of being adequately informed about test quality. The commenter believed it is not possible to assess the analytical and clinical validity of all genetic health risks a company might offer by conducting a one-time review of its ‘assessment system’, as proposed by FDA. Such oversight, it is argued, will only allow FDA to assess the analytical and clinical validity, and ‘mitigate the risks of false negatives and positives’, for tests initially proposed by the company during this one-time review. The commenter believed that it does not appear that there will be assessment of the analytical or clinical validity of subsequent tests offered, nor any assessment of the risks to the consumer of an incorrect result. This commenter believed that FDA’s proposal to exempt one-time FDA reviewed genetic health risk assessment system devices will not prevent scientifically invalid tests from being marketed to the public and lacks a comprehensive assessment. Further, the commenter argued that, after undergoing the one-time FDA review for genetic health risk assessment tests, companies would be able to market subsequent tests to the public as part of the same system and declare that the tests meet FDA’s standards. Such tests would not be held to any specific standards of analytical or clinical validity. The public would likely assume (and purveyors would likely advertise) that FDA had reviewed and approved such tests as valid even though they had not been reviewed by the Agency. The commenter also argued that there is a vast range of quality (i.e., scientific merit) of direct-to-consumer (DTC) genetic health risk assessment tests on the market. The commenter argued that the market’s current mixing of entertainment tests, which make claims unsubstantiated by the scientific literature, with those tests which have a clinical utility, are clinically valid, and can be supported by current scientific
literature, is particularly confusing for
the average consumer.

(Response) We agree that the concerns
raised above are important. These
concerns were considered during our
review and development of the initial
classification regulation for genetic
health risk assessment system devices
and in our consideration of whether to
exempt one-time FDA reviewed genetic
health risk assessment system devices
from the 510(k) requirement. We believe
these concerns have been addressed and
accounted for in our determination that
the 510(k) requirement is not necessary
to provide a reasonable assurance of
safety and effectiveness for these
devices. We outline our rationale below.

Consumer understanding of genetic
risk is clearly an important issue that
was considered extensively by FDA in
the context of genetic health risk
assessment system devices. This issue
was balanced with the increasing desire
from the public to learn more about
one’s own genetic makeup and how it
affects one’s health conditions. To
ensure that the tests and test reports
are presented to the lay consumer in a
manner that is understandable, we
employed several requirements.

Consumer understanding of the tests
and associated test reports is assured by
user comprehension study
requirements, specific labeling
requirements for these over-the-counter
(OTC) tests, and general requirements
for devices. The special labeling
requirements for these devices under § 866.5950(b)(21 CFR 866.5950(b))
include providing information on the
manufacturer’s website about frequently
asked questions, available professional
guidelines, and how to obtain access to
a genetic counselor.

A. User Comprehension Study

A user comprehension study is
required under § 866.5950(b)(3)(ii)(M).
The required user comprehension study
must assess comprehension of the test
process and results by potential users of
the test with pre- and post-test user
comprehension studies. This study must
be conducted on a statistically sufficient
sample size of non-trained individuals
who represent the demographics of the
United States as well as a diverse range
of age and educational levels. The study
must include directly evaluating a
representative sample of the material
being presented to the user during use
of the test. The test that is given to the
participants must be informed by a
physician and/or genetic counselor that
identifies the appropriate general and
variant-specific concepts contained
within the material being tested in the
user comprehension study to ensure
that all relevant concepts are
incorporated in the study as well as
having included the definition of the
target condition being tested and related
symptoms, explain the intended use and
limitations of the test, explain the
relevant ethnicities in regard to the
variant tested, explain genetic health
risks and relevance to the user’s
ethnicity, and assess participants’
ability to understand the following
comprehension concepts: The test’s
limitations, purpose, appropriate action,
test results, and other factors that may
have an impact on the test results. The
outcome of this study has to meet
rigorous standards, including meeting
predefined primary endpoint criteria,
including a minimum of a 90 percent or
greater overall comprehension rate (i.e.,
selection of the correct answer) for each
comprehension concept. In addition, the
testing must follow a format where users
have limited time to complete the
studies (such as an onsite survey format
and a one-time visit with a cap on the
maximum amount of time that a
participant has to complete the tests).
From our experience with user
comprehension studies, the Agency
believes that meeting or exceeding
these user comprehension study requirements
ensures that the materials presented to
the user are adequate for OTC use. The
information the test provider must
provide on its website includes a
summary table of comprehension rates
regarding comprehension concepts (e.g.,
purpose of test, test results, test
limitations, ethnicity relevance for
the test results, etc.) for each study report.

B. Frequently Asked Questions

The manufacturer’s website must have
a frequently asked questions section in
the summary and technical information
sections under § 866.5950(b)(3)(ii)(C)(3)
and (b)(3)(iii)(L)(3). For the frequently asked
questions sections, information must be
included that is specific for each
variant/disease pair that is reported and
scientifically valid and supported by
corresponding publications. Further
information must be included that
explains the health condition/disease
being tested, the purpose of the test, the
information the test will and will not
provide, the relevance of race and
ethnicity on the test results, information
about the population to which the
variants in the test is most applicable,
the meaning of the result(s), other risks
factors that contribute to disease,
appropriate followup procedures, how
the results of the test may affect the
user’s lifestyle choices and/or
inform lifestyle choices and/or
conversations with a healthcare
professional. This assessment system is
for OTC use. This device does not
determine the person’s overall risk of
developing a disease.

The limitations that are most
important for lay users to know about
the intended use of these tests that fall
under this device type are conveyed via
the limiting statements required, under
§ 866.5950(b)(1)(i), to be provided on
the § 809.10 compliant labeling and any
pre-purchase page and test report
provided regarding how a user obtains access to
a genetic counselor, board-certified
clinical molecular geneticist, or
equivalent healthcare professional
regarding the results of a user’s test.

D. Genetic Health Risk Assessment System Tests

The tests that fall under the genetic
health risk assessment system regulation
are identified in the regulation in
§ 866.5950(a) as a qualitative in vitro
molecular diagnostic system used for
detecting variants in genomic
deoxyribonucleic acid (DNA) isolated
from human specimens that will
provide information to users about their
genetic risk of developing a disease to
inform lifestyle choices and/or
conversations with a healthcare
professional. This assessment system is
for OTC use. This device does not
 determine the person’s overall risk of
developing a disease.

Likely the test labeling information
provided by the test manufacturer will
not be the sole source of information
that the consumer is seeking or even
requires. For this reason, there are
requirements under
§ 866.5950(b)(3)(ii)(C)(2) and
(b)(3)(iii)(L)(2) that the manufacturer of
the test provide a pre-purchase page in
the summary and technical information
sections that includes information
regarding professional guidelines for
testing specific genes and variants.

Similar information must be provided in
the frequently asked questions section
found in the summary and technical
information sections on the
manufacturer’s website, under
§ 866.5950(b)(3)(ii)(C)(3) and
(b)(3)(iii)(L)(3). These frequently asked
questions sections must include a
statement about the current professional
guidelines for testing these specific
gene(s) and variant(s) and, if guidelines
do not exist for certain genes or variants
being tested for, then this information
must be provided as well. Further, to
tailor more personalized support,
under § 866.5950(b)(1)(i)(E), test
manufacturers are required to provide
information in the § 809.10 (21 CFR
809.10) compliant labeling and any
pre-purchase page and test report
regenerated regarding how a user obtains access to
a genetic counselor, board-certified
clinical molecular geneticist, or
equivalent healthcare professional
regarding the results of a user’s test.

C. Resources

25912 Federal Register / Vol. 83, No. 108 / Tuesday, June 5, 2018 / Rules and Regulations
not intended to diagnose a disease, tell you anything about your current state of health, or be used to make medical decisions, including whether or not you should take a medication or how much of a medication you should take. The limitations that are most important for healthcare professionals to know about the intended use of tests that fall under this device type are, under § 866.5950(b)(1)(iii), required to be provided in the § 809.10 labeling and any test report generated. These limitations include that the test is intended to provide users with their genetic information to inform lifestyle decisions and conversations with their doctor or other healthcare professional and that any diagnostic or treatment decisions should be based on testing and/or other information that a healthcare professional determines to be appropriate for a patient.

E. Rigorous Validation Requirements

FDA believes the analytical validation requirements are sufficiently detailed in the special controls under § 866.5950(b)(3)(iii)(f) that test providers will have no difficulty in appropriately following these requirements. A high accuracy requirement is necessary for tests that are provided under this regulation and accuracy point estimates for all variants is required to be 99 percent or higher under § 866.5950(b)(3)(iii)(f)(I)(vii) or else they cannot be claimed or reported. Once FDA has reviewed one test that demonstrates this level of accuracy, then the test provider has demonstrated an ability to meet the accuracy requirements for additional similar tests offered.

F. Four Important Limitations on the Scope of the Classification Regulation

FDA agrees that there are four important express limitations to the types of tests that can be offered under this classification regulation even when these special controls are met. Tests cannot be offered under this classification regulation that are indicated for prenatal testing; predisposition for cancer where the result of the test may lead to prophylactic screening, confirmatory procedures, or treatments that may incur morbidity or mortality to the patient; assessing the presence of genetic variants that impact the metabolism, exposure, response, risk of adverse events, dosing, or mechanisms of prescription or OTC medications; or assessing the presence of deterministic autosomal dominant variants.

G. False or Misleading Claims

It is a prohibited act for devices to have labeling that is false or misleading in any particular manner, and thus FDA would deem such device to be misbranded under section 502(a) of the FD&C Act (21 U.S.C. 352(a)). This prohibition would include prohibiting the manufacturer of a genetic health risk assessment test device from falsely or misleadingly representing a test as having been part of an original FDA cleared device when it was added subsequently to FDA clearance. This prohibition would also include falsely or misleadingly representing the analytical or clinical validity of one of its tests. In addition, under section 502(c) of the FD&C Act, it is a prohibited act that the FDA would deem a device to be misbranded if any information required on the labeling of a device by FDA or under the FD&C Act is not placed prominently thereon with such conspicuousness and in such terms, as to render it likely to be read and understood by the ordinary individual under customary conditions of purchase and use. Thus, a genetic health risk assessment test device for which a manufacturer later modified the formerly compliant labeling to make the labeling misleading was not likely to be read and understood by the ordinary individual under customary conditions of purchase and use would be a misbranded device.

H. Conclusion

In summary, all tests that are marketed under this classification regulation must meet the general controls and the special controls that are specified in the regulation. Ability of a manufacturer to meet these special controls is demonstrated during the one-time review. Even after the one-time review, the general controls and special controls must continue to be met, including for all tests added or modified after the one-time review of a manufacturer’s device.

IV. Limitations on Exemptions

FDA has determined that 510(k) is not necessary to assure the safety and effectiveness of the class II devices listed in table 1. This determination is based, in part, on the Agency’s knowledge of the device, including past experience and relevant reports or studies on device performance (as appropriate), the applicability of general and special controls, and the Agency’s ability to limit an exemption.

A. General Limitations of Exemptions

FDA’s exemption from 510(k) for class II devices listed in table 1 applies only to those devices that have existing or reasonably foreseeable characteristics of commercially distributed devices within that generic type, or, in the case of in vitro diagnostic devices, for which a misdiagnosis, as a result of using the device, would not be associated with high morbidity or mortality. A manufacturer of a listed device is still required to submit a 510(k) to FDA before introducing a device or delivering it for introduction into commercial distribution when the device meets any of the conditions described in §§ 862.9 to 892.9 (21 CFR 862.9 to 21 CFR 892.9).

B. Partial Limitations of Exemptions

In addition to the general limitations, FDA may also partially limit an exemption from 510(k) requirements to specific devices within a listed device type when initial Agency assessment determines that the factors laid out in the Class II 510(k) Exemption Guidance do not weigh in favor of exemption for all devices in a particular group. In such situations where a partial exemption limitation has been identified, FDA has determined that premarket notification is necessary to provide a reasonable assurance of safety and effectiveness for these devices. In table 1, for example, FDA is listing the exemption of the genetic health risk assessment system, but limits the exemption to such devices that have received a first-time FDA marketing authorization (e.g., 510(k) clearance) for the genetic health risk assessment system (a “one-time FDA reviewed genetic health risk assessment system”). FDA has determined that a one-time FDA review (e.g., premarket notification) of a genetic health risk assessment system is necessary to provide reasonable assurance of the safety and effectiveness of the device. FDA has determined that a one-time FDA review of a genetic health risk assessment system is necessary to mitigate the risk of false negatives and false positives by ensuring that certain information be submitted to FDA to allow the Agency to assess the safety and effectiveness of the devices as well as to ensure the devices perform to acceptable standards.

Exemption from the requirement of 510(k) does not exempt a device from other applicable regulatory controls under the FD&C Act, including the applicable general and special controls. This exemption from 510(k), subject to the limitations described above, is immediately in effect for the device types identified in table 1. This will reduce regulatory burdens on the medical device industry and will eliminate private costs and
expenditures required to comply with Federal regulations.

V. List of Class II Devices

FDA is identifying the following list of class II devices that will no longer require premarket notification under section 510(k) of the FD&C Act, subject to the general limitations to the exemptions found in §§ 862.9 to 892.9 and any partial exemption limitations identified in table 1:

<table>
<thead>
<tr>
<th>TABLE 1—CLASS II DEVICES</th>
</tr>
</thead>
<tbody>
<tr>
<td>21 CFR section</td>
</tr>
<tr>
<td>862.1840</td>
</tr>
<tr>
<td>866.5950</td>
</tr>
<tr>
<td>876.1500</td>
</tr>
<tr>
<td>880.6710</td>
</tr>
<tr>
<td>884.5960</td>
</tr>
</tbody>
</table>

FDA is revising the name of product code PUP to further clarify the device type that this product code is intended to represent. The device type was previously “Endoscope Maintenance System.” To more accurately reflect the devices which fall within this device type (product code PUP), the device type has been renamed “Endoscope Disinfectant Basin.” Specifically, these devices are described as “Wall-mounted tube(s) for holding disinfectant solution and endoscope insertion tubes and accessories.” This description has not changed since publication of the November 2017 notice.

VI. Analysis of Environmental Impact

The Agency has determined under 21 CFR 25.30(h) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

VII. Paperwork Reduction Act of 1995

This final order refers to previously approved collections of information found in other FDA regulations and guidance. These collections of information are subject to review by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501–3520). The collections of information in part 807, subpart E, regarding labeling, have been approved under OMB control number 0910–0120; and the collections of information in 21 CFR parts 801 and 809, regarding labeling, have been approved under OMB control number 0910–0485.

List of Subjects

21 CFR Part 862

Medical devices.

21 CFR Part 866

Biologics, Laboratories, Medical devices.

21 CFR Parts 876, 880, and 884

Medical devices. Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs, 21 CFR parts 862, 866, 876, 880, and 884 are amended as follows:

PART 862—CLINICAL CHEMISTRY AND CLINICAL TOXICOLOGY DEVICES

1. The authority citation for part 862 continues to read as follows:


2. In § 862.1840, revise paragraph (b) introductory text to read as follows:

§ 862.1840 Total 25-hydroxyvitamin D mass spectrometry test system.

* * * * *

(b) Classification. Class II (special controls). The device is exempt from the premarket notification procedures in part 807, subpart E, of this chapter subject to the limitations in § 862.9. The device must comply with the following special controls:

§ 866.5950 Genetic health risk assessment system.

* * * * *

PART 866—IMMUNOLOGY AND MICROBIOLOGY DEVICES

3. The authority citation for part 866 continues to read as follows:


4. In § 866.5950, revise paragraph (b) introductory text to read as follows:

§ 866.5950 Genetic health risk assessment system.

* * * * *

(b) Classification. Class II (special controls). The genetic health risk assessment system device, when it has previously received a first-time FDA marketing authorization (e.g., 510(k) clearance) for the genetic health risk assessment system (a “one-time FDA reviewed genetic health risk assessment system”), is exempt from the premarket notification procedures in part 807, subpart E, of this chapter subject to the limitations in § 866.9. The device must comply with the following special controls:

* * * * *

PART 876—GASTROENTEROLOGY–UROLOGY DEVICES

5. The authority citation for part 876 continues to read as follows:


6. In § 876.1500, revise paragraph (b)(1) to read as follows:

§ 876.1500 Endoscope and accessories.

* * * * *

(b) * * *

(1) Class II (performance standards). The device, when intended as an endoscope disinfectant basin, which consists solely of a container that holds disinfectant and endoscopes and accessories, is exempt from the premarket notification procedures in part 807, subpart E, of this chapter subject to the limitations in § 876.9.

* * * * *
PART 880—GENERAL HOSPITAL AND PERSONAL USE DEVICES

7. The authority citation for part 880 continues to read as follows:


8. In § 880.6710, revise paragraph (b) to read as follows:

§ 880.6710 Medical ultraviolet water purifier.

*(b) Classification. Class II (performance standards). The device is exempt from the premarket notification procedures in part 807, subpart E, of this chapter subject to the limitations in § 880.9.*

PART 884—OBSTETRICAL AND GYNECOLOGICAL DEVICES

9. The authority citation for part 884 continues to read as follows:


10. In § 884.5960, revise paragraph (b) to read as follows:

§ 884.5960 Genital vibrator for therapeutic use.

*(b) Classification. Class II (performance standards). The device is exempt from the premarket notification procedures in part 807, subpart E, of this chapter subject to the limitations in § 884.9.*

DEPARTMENT OF VETERANS AFFAIRS

38 CFR Part 17

RIN 2900–AQ15

Case Management Services Grant Program

AGENCY: Department of Veterans Affairs.

ACTION: Interim final rule.

SUMMARY: The Department of Veterans Affairs (VA) is amending its regulations that govern programs benefitting homeless veterans to implement a new statutory requirement to establish a new grant program that will provide case management services to improve the retention of housing by veterans who were previously homeless and are transitioning to permanent housing and to veterans who are at risk of becoming homeless. The grant program established by this interim final rule will be an essential part of VA’s attempts to eliminate homelessness among the veteran population.

DATES: This final rule is effective June 5, 2018. Comments must be received on or before August 6, 2018.

ADDRESSES: Written comments may be submitted through http://www.Regulations.gov; by mail or hand-delivery to: Director, Regulation Policy and Management (00REG), Department of Veterans Affairs, 810 Vermont Ave. NW, Room 1063B, Washington, DC 20420; or by fax to (202) 273–9026. (This is not a toll-free telephone number.) Comments should indicate that they are submitted in response to “RIN 2900–AQ15—Case Management Services Grant Program.” Copies of comments received will be available for public inspection in the Office of Regulation Policy and Management, Room 1063B, between the hours of 8 a.m. and 4:30 p.m., Monday through Friday (except holidays). Please call (202) 461–4902 for an appointment. (This is not a toll-free telephone number.) In addition, during the comment period, comments may be viewed online through the Federal Docket Management System (FDMS) at http://www.Regulations.gov.

FOR FURTHER INFORMATION CONTACT: Jeffery Quarles, Director, Grant and Per Diem Program, (10NC1HM), VA National Grant and Per Diem Program Office, 10770 N 46th Street, Suite C–200, Tampa, FL 33617, (877) 332–0334. (This is a toll-free number.)

SUPPLEMENTARY INFORMATION: In an effort to reduce homelessness in the veteran population, Congress has required VA to expand its benefits for homeless veterans by establishing a new grant program to provide funds to organizations within communities that will provide case management services to improve the retention of housing by veterans who were previously homeless and are transitioning to permanent housing and to veterans who are at risk of becoming homeless. See Public Law 114–315, sec. 712 (Dec. 16, 2016) (codified at 38 U.S.C. 20420). This interim final rule adds this new case management program to VA’s Homeless Providers Grant and Per Diem Program regulations by adding a new subpart G to 38 CFR part 61 to accurately reflect these changes in law. The new case management program will mirror existing homeless grant per diem programs as much as possible for ease of administrating and running the new grant program.